Pharmaceutical - Diabetes, Johnson & Johnson


Current filters:

DiabetesJohnson & Johnson

Popular Filters

UK’s NICE backs Janssen’s Invokana for type 2 diabetes


Janssen, a subsidiary of US health care giant Johnson & Johnson, said today that it welcomes the publication…

DiabetesInvokanaJanssenJohnson & JohnsonPharmaceuticalPricingRegulationUK

NICE consults on draft guidance backing Invokana, as drug debuts in the UK


UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

US FDA calls for more data on Janssen’s fixed dose diabetes drug

US FDA calls for more data on Janssen’s fixed dose diabetes drug


US health care giant Johnson & Johnson has received a complete response letter from the Food and Drug…

canagliflozinDiabetesJanssenJohnson & JohnsonmetforminNorth AmericaPharmaceuticalRegulation

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA


It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide


Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA


There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

FDA panel backs J&J diabetes drug Invokana (canagliflozin)


The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

canagliflozinDiabetesInvokanaJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021


The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA


US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag International…

Anti-viralscanagliflozinDiabetesEgriftaEuropeFerrer InternacionalJanssenJohnson & JohnsonPharmaceuticalRegulation

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy


Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

Russia’s type 2 diabetes drug market will grow to $1.7 billion in 2015


Russia’s type 2 diabetes drug market will grow more than seven percent annually from $1.2 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesEuropeJohnson & JohnsonMarkets & MarketingPharmaceutical

Back to top